TRIB (Trinity Biotech) Net Income (Continuing Operations): $-37.38 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TRIB Trinity Biotech PLC TRIB
34 GF Score
Price $9.87
GF Value $23.52
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Trinity Biotech Net Income (Continuing Operations)?

Trinity Biotech TRIB +1.96% 34 Net Income (Continuing Operations) is $-37.38 Mil as of Dec. 2025. GuruFocus rates TRIB with a GF Score™ of 34/100 and a GF Value™ of $23.52 (Possible Value Trap). The stock has 7 warning signs investors should review.

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Trinity Biotech's Net Income (Continuing Operations) for the six months ended in Dec. 2025 was $-22.61 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Dec. 2025 was $-37.38 Mil.

Trinity Biotech  (NAS:TRIB) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Trinity Biotech Net Income (Continuing Operations) Related Terms

Trinity Biotech Net Income (Continuing Operations) Historical Data

* Premium members only.

The historical data trend for Trinity Biotech's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Trinity Biotech Net Income (Continuing Operations) Chart

Trinity Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net Income (Continuing Operations)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.85 -43.59 -36.87 -31.22 -37.38

Trinity Biotech Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Net Income (Continuing Operations) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -12.22 -10.07 -21.14 -14.76 -22.61
TRIB
34GF Score
Trinity Biotech PLC TRIB
Net Income (Continuing Operations) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Trinity Biotech Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-37.38 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Net Income (Continuing Operations) of $-37.38 Mil mean?
Trinity Biotech (TRIB) has a Net Income (Continuing Operations) of $-37.38 Mil as of Dec. 2025. Net Income (Continuing operations) is the total net earnings from a company's continuing operations. View historical data on Trinity Biotech and its competitors.
Is Trinity Biotech's Net Income (Continuing Operations) too high?
Trinity Biotech's current Net Income (Continuing Operations) is $-37.38 Mil. Overall, Trinity Biotech has a GF Score™ of 34/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Trinity Biotech's Net Income (Continuing Operations) compare to ICCM and AIDX?
Trinity Biotech's Net Income (Continuing Operations) of $-37.38 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Income (Continuing Operations) for a Medical Devices & Instruments company?
A good Net Income (Continuing Operations) depends on the Medical Devices & Instruments industry context. However, Net Income (Continuing Operations) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Income (Continuing Operations) mean?
A high Net Income (Continuing Operations) can signal that a stock is expensive relative to its fundamentals. Net Income (Continuing operations) is the total net earnings from a company's continuing operations. View historical data on Trinity Biotech and its competitors. Trinity Biotech's current Net Income (Continuing Operations) is $-37.38 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Trinity Biotech stock overvalued right now?
Based on GuruFocus' analysis, Trinity Biotech (TRIB) is currently considered Possible Value Trap. The stock's GF Value™ is $23.52, compared to a current price of $9.87 — trading 58% below its estimated fair value. The current Net Income (Continuing Operations) is $-37.38 Mil. Trinity Biotech's overall GF Score™ is 34/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Income (Continuing Operations) calculated?
Net Income (Continuing Operations) is calculated from a company's financial statements. For Trinity Biotech (TRIB), the current Net Income (Continuing Operations) is $-37.38 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Trinity Biotech (TRIB) Overvalued in 2026?

Based on GuruFocus' analysis, Trinity Biotech stock appears to be undervalued. The current stock price of $9.87 is trading 58% below its estimated GF Value™ of $23.52. GuruFocus considers Trinity Biotech to be Possible Value Trap.

Key valuation signals for TRIB:

  • Net Income (Continuing Operations): $-37.38 Mil
  • GF Value™: $23.52 vs. price of $9.87 (58% below fair value)
  • GF Score™: 34/100 with 7 warning signs

No single metric tells the full story. See the TRIB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Trinity Biotech Business Description

Address IDA Business Park, Bray, County Wicklow, Dublin, IRL, A98 H5C8
Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has three segments, namely the Americas, Asia/Africa, and Europe, from which it derives a majority of its revenue from the Americas segment.
34GF Score

Get the complete analysis for TRIB

Net Income (Continuing Operations) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.87
Price
$23.52
GF Value